Patients / Clinical Trials / Advancing Inclusive Research

ADVANCING INCLUSIVE RESEARCH^®

Always Design with Patient Equity in Mind

Clinical studies offer people with serious and life-threatening diseases a chance to receive investigational medicines that can potentially improve outcomes. At Genentech, we are deeply committed to addressing barriers to clinical study participation and advancing inclusive research.

Learn more about how Genentech seeks to create more equitable health outcomes through inclusive research.

WHY INCLUSIVE RESEARCH?

More must be done to ensure clinical trial participants are representative of the entire patient population.

<10% Today, fewer than 10% of U.S. patients participate in clinical trials and of those only 5-15% are non-European.¹
~50% Yet, approximately half of the U.S. population is projected to be non-white by 2044.²
>94% More than 94% of genomic material available to scientists is of European ancestry.³

STRATEGIC FOCUS AREAS

REIMAGINING CLINICAL STUDIES

EMPOWERING PATIENTS & PROVIDERS

COLLABORATING WITH EXTERNAL PARTNERS

Click each dropdown to see our impact in action:

Advancing Inclusive Research^® (AIR) is an innovative cross-functional approach taken to increase representation of historically under-studied and underrepresented patients in clinical research.

Genentech’s efforts in inclusive research focus on diseases that disproportionately or differentially affect patients across races, ethnicities, and ancestries. We are actively designing studies to learn new insights and build a knowledge base for underrepresented communities. Key inclusive studies include:

CHIMES: A Phase IV study for Black/African American and Hispanic/Latino patients with relapsing-remitting multiple sclerosis

CHIMES exceeded its target, enrolling 150 Black or Hispanic/Latino patients more than two months ahead of schedule.

ELEVATUM: A Phase IV study for Black/African American, Hispanic/Latino, American Indian and Pacific Islander patients with diabetic macular edema

ELEVATUM enrolled 124 patients one month ahead of schedule.

CATORI: An observational study to define current care pathways for American Indian and Alaska Native patients requiring specialty care De-Centralized Trial methods

CATORI is revealing insights about healthcare experiences for American Indians or Alaska Natives.

We are creating culturally relevant resources to reduce bias in care delivery and expand access to healthcare information for patients and healthcare providers.

Partnering with the Advancing Inclusive Research Site Alliance, we have published multiple award-winning educational videos to provide easy-to-understand information about clinical studies and the importance of inclusive clinical research.

Learn more by viewing our Clinical Trials YouTube Playlist.

Clinical research studies help us develop medicines that are safe and effective. These brochures provide easy-to-understand information on clinical research studies with emphasis on representation and inclusion. These materials were co-created with sites in the Advancing Inclusive Research Site Alliance.

Genentech works with diverse teams of experts who strategize on how to reach more representative patient populations.

The External Council for Advancing Inclusive Research
Includes physician thought leaders, academic researchers, and patient advocates with expertise in oncology, ophthalmology and neuroscience clinical care, research and genomics.
Advancing Inclusive Research Site Alliance Champions
Includes oncology and ophthalmology clinical investigators, physicians, researchers and community educators.

Collectively, these experts understand the needs of their communities and know how to build trust with patients. By identifying best practices with these partners, we are able to amplify learnings within all our studies.

ADVANCING INCLUSIVE RESEARCH^® SITE ALLIANCE

The U.S. Advancing Inclusive Research Site Alliance is a coalition of clinical research sites in oncology and ophthalmology that partner with Genentech to advance the representation of diverse patient populations in our clinical trials, test recruitment and retention approaches, and establish best practices that can be leveraged across the industry to help achieve health equity. Meet our site alliance champions.

I believe inclusive research is research—full stop. One day we won’t need the qualifier inclusive because all clinical studies will represent the diversity of the patients we serve.

— Quita Highsmith, MBA, Vice President & Chief Diversity Officer, Genentech

Health Equity

We believe that advancing health equity is an ongoing process of addressing barriers that people face when accessing healthcare.

Clinical Trial Information

Information and support about Genentech sponsored trials.

Phone: (888) 662-6728
Monday-Friday, 5am-5pm PT

Genentech Patient Foundation

Provides free medicine to people without insurance coverage or who can’t pay for their Genentech medicines.

A Vision for All: Bridging Equity Gaps in Eye Health Research

U.S. Advancing Inclusive Research Site Alliance Expands Into Ophthalmology

At Roche and Genentech, we believe that improving health outcomes for all patients is core to our mission, and we are committed to being industry leaders in delivering improved health outcomes for all...

At Roche and Genentech, we believe that improving health outcomes for all patients is core to our mission, and we are committed to being industry leaders in delivering improved health outcomes for all.

In the increasingly diverse world around us, the time is now for research and clinical development to ensure greater inclusion of patients across racial and ethnic groups in support of optimizing health outcomes for all patients worldwide.

Because disease outcomes and drug responses can vary across populations, research must include patients who are racially, ethnically, and gender representative of those who experience disease. We are deeply committed to addressing barriers to clinical trial participation, diversifying genetic data for scientific discovery, and increasing access to innovative diagnostic and therapeutic solutions, by advancing inclusive research.

By building trusted partnerships with patients, providers and across the healthcare ecosystem, we can collectively combine scientific advances, new technologies and real-world data to drive scientific innovation and create new standards for inclusive research.

As we strive to deliver more patient benefit, we are passionately addressing healthcare disparities in order to deliver ever more personalized healthcare solutions for all patients.

Click here to read Roche's position on Race, Ethnicity and Genetic Ancestry in Clinical Research.

^{REFERENCES
1 Nabhan C, Choueiri TK, Mato AR. Rethinking Clinical Trials Reform During the COVID-19 Pandemic. JAMA Oncol. 2020;6(9):1327-1329. doi:10.1001/jamaoncol.2020.3142; for non-Caucasian participation (Hispanic and Latino): Coakley M, Fadiran EO, Parrish LJ, Griffith RA, Weiss E, Carter C. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials . J Womens Health (Larchmt). Jul 2012;21(7):713-6. doi:10.1089/jwh.2012.3733
2 Colby SL, Ortman JM. Rethinking Projections of the Size and Composition of the U.S. Population: 2014 to 2060.
3 Genomic Data Source: Rethinking Total GWAS Participants Diversity. GWAS Diversity Monitor.}

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.